Skip to the content
  • Our Company
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science & Innovation
    • Our Approach
    • Our Pipeline
  • Culture
  • Media
    • Resources
    • News
  • News
  • Contact
  • Our Company
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science & Innovation
    • Our Approach
    • Our Pipeline
  • Culture
  • Media
    • Resources
    • News
  • News
  • Contact

Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis.

  • Scientific Publication
  • August 13, 2019
  • Scientific Publication
  • August 13, 2019

Mishra N, et al. (2019) “Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis.” mBio. 10(4). pii: e01903-19. doi: 10.1128/mBio.01903-19

ABSTRACT

Acute flaccid myelitis (AFM) has caused motor paralysis in >560 children in the United States since 2014. The temporal association of enterovirus (EV) outbreaks with increases in AFM cases and reports of fever, respiratory, or gastrointestinal illness prior to AFM in >90% of cases suggest a role for infectious agents. Cerebrospinal fluid (CSF) from 14 AFM and 5 non-AFM patients with central nervous system (CNS) diseases in 2018 were investigated by viral-capture high-throughput sequencing (VirCapSeq-VERT system). These CSF and serum samples, as well as multiple controls, were tested for antibodies to human EVs using peptide microarrays. EV RNA was confirmed in CSF from only 1 adult AFM case and 1 non-AFM case. In contrast, antibodies to EV peptides were present in CSF of 11 of 14 AFM patients (79%), significantly higher than controls, including non-AFM patients (1/5 [20%]), children with Kawasaki disease (0/10), and adults with non-AFM CNS diseases (2/11 [18%]) (P = 0.023, 0.0001, and 0.0028, respectively). Six of 14 CSF samples (43%) and 8 of 11 sera (73%) from AFM patients were immunoreactive to an EV-D68-specific peptide, whereas the three control groups were not immunoreactive in either CSF (0/5, 0/10, and 0/11; P = 0.008, 0.0003, and 0.035, respectively) or sera (0/2, 0/8, and 0/5; P = 0.139, 0.002, and 0.009, respectively).

PrevPrevious
NextNext
  • Our Team
  • Our Pipeline
  • Partner
  • Resources
  • News
  • Careers
  • Contact
  • Our Team
  • Our Pipeline
  • Partner
  • Resources
  • News
  • Careers
  • Contact
  • CONNECT ON LINKEDIN

Copyright © 2024 Nimble Therapeutics, Inc